{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T19:08:39Z","timestamp":1789412919124,"version":"build-2803163510"},"reference-count":35,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,2,15]]},"DOI":"10.2169\/internalmedicine.5432-20","type":"journal-article","created":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T22:11:33Z","timestamp":1613340693000},"page":"507-516","source":"Crossref","is-referenced-by-count":4,"title":["Factors Associated with Hepatitis B Surface Antigen Kinetics and Responses in Pegylated Interferon Alpha-2a Monotherapy for Patients with Chronic Hepatitis B"],"prefix":"10.2169","volume":"60","author":[{"given":"Norio","family":"Itokawa","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Atsukawa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Japan"},{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Tsubota","sequence":"additional","affiliation":[{"name":"Core Research Facilities, The Jikei University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritomo","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology and Hepatology, Otakanomori Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Toyoda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ogaki Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takaguchi","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Kagawa Prefectural Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hiraoka","sequence":"additional","affiliation":[{"name":"Gastroenterology Center, Ehime Prefectural Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Senoh","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Kagawa Prefectural Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Koeda","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Okubo","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeang","family":"Arai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korenobu","family":"Hayama","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Nakagawa-Iwashita","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisa","family":"Kondo","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Iwakiri","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. World Health Organization. Global Hepatitis Report 2017 [Internet]. [cited 2019 Feb 8]. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255016\/9789241565455-eng.pdf;jsessionid=B8D6C8B41115B5710E70A74A4954EF81?sequence=1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Dienstag JL. Hepatitis B virus infection. N Engl J Med 359: 1486-1500, 2008.","DOI":"10.1056\/NEJMra0801644"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 26: 153-161, 2006.","DOI":"10.1055\/s-2006-939753"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Simonetti J, Bulkow L, McMahon BJ, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 51: 1531-1537, 2010.","DOI":"10.1002\/hep.23464"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 142: 1140-1149. e3; quiz e13-e4, 2012.","DOI":"10.1053\/j.gastro.2012.02.007"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: from discovery to regulatory approval. Hepatology 66: 1296-1313, 2017.","DOI":"10.1002\/hep.29323"},{"key":"7","unstructured":"7. Nagaoka S, Abiru S, Komori A, et al. Hepatic flares promote rapid decline of serum hepatitis B surface antigen (HBsAg) in patients with HBsAg seroclearance: A long-term follow-up study. Hepatol Res 46: E89-E99, 2016."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Zoulim F, Locarnini S. Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver Int 33 (Suppl): S116-S124, 2013.","DOI":"10.1111\/liv.12069"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. van Bommel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside\/nucleotide analogues. Hepatology 51: 73-80, 2010.","DOI":"10.1002\/hep.23246"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gish RG, Chang TT, Lai CL, et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 17: 16-22, 2010.","DOI":"10.1111\/j.1365-2893.2009.01146.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Suzuki F, Hosaka T, Suzuki Y, et al. Long-term outcome of entecavir treatment of nucleos (t) ide analogue-na\u00efve chronic hepatitis B patients in Japan. J Gastroenterol 54: 182-193, 2019.","DOI":"10.1007\/s00535-018-1502-y"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Micco L, Peppa D, Loggi E, et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol 58: 225-233, 2013.","DOI":"10.1016\/j.jhep.2012.09.029"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 136: 2169-2179.e1-4, 2009.","DOI":"10.1053\/j.gastro.2009.03.006"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 135: 459-467, 2008.","DOI":"10.1053\/j.gastro.2008.05.031"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet 19: 390-399, 1990.","DOI":"10.2165\/00003088-199019050-00003"},{"key":"16","unstructured":"16. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 10: 298-305, 2003."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 33: 998-1002, 2000.","DOI":"10.1016\/S0168-8278(00)80135-X"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Suzuki F, Arase Y, Suzuki Y, et al. Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan. J Gastroenterol 47: 814-822, 2012.","DOI":"10.1007\/s00535-012-0548-5"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Shindo M, Hamada K, Nishioji K, Muramatsu A, Oda Y, Okuno T. The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B. J Gastroenterol 39: 260-267, 2004.","DOI":"10.1007\/s00535-003-1293-6"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 137: 2002-2009, 2009.","DOI":"10.1053\/j.gastro.2009.08.061"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Masaki K, Suzuki F, Hara T, et al. Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection. Virol J 12: 225, 2015.","DOI":"10.1186\/s12985-015-0453-7"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 52: 1251-1257, 2010.","DOI":"10.1002\/hep.23844"},{"key":"23","unstructured":"23. Piratvisuth T, Marcellin P, Popescu M, Kapprell HP, Rothe V, Lu ZM. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int 7: 429-436, 2013."},{"key":"24","unstructured":"24. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 49: 1141-1150, 2009."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Usman Z, Mijo\u010devi\u0107 H, Karimzadeh H, et al. Kinetics of hepatitis B surface antigen quasispecies during REP 2139-Ca therapy in HBeAg-positive chronic HBV infection. J Viral Hepat 2019: 1454-1464, 2019 26.","DOI":"10.1111\/jvh.13180"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Fujita K, Mimura S, Iwama H, et al. Serum miRNAs predicting sustained HBs antigen reduction 48 weeks after pegylated interferon therapy in HBe antigen-negative patients. Int J Mol Sci 19: 1940, 2018.","DOI":"10.3390\/ijms19071940"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Matsumoto A, Tanaka E, Suzuki Y, et al. Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos (t) ide analogs in patients with chronic hepatitis B. Hepatol Res 42: 139-149, 2012.","DOI":"10.1111\/j.1872-034X.2011.00910.x"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis patients with HIV\/HCV co-infection. Hepatology 43: 1317-1325, 2006.","DOI":"10.1002\/hep.21178"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Sonneveld MJ, Janssen HL. Chronic hepatitis B: peginterferon or nucleos (t) ide analogues? Liver Int 31 (Suppl): S78-S84, 2011.","DOI":"10.1111\/j.1478-3231.2010.02384.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352: 2682-2695, 2005.","DOI":"10.1056\/NEJMoa043470"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 49: 1151-1157, 2009.","DOI":"10.1002\/hep.22744"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 34: 1021-1026, 2001.","DOI":"10.1053\/jhep.2001.28459"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut 54: 1604-1609, 2005.","DOI":"10.1136\/gut.2004.062208"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Sonneveld MJ, Zoutendijk R, Flink HJ, Zwang L, Hansen BE, Janssen HL. Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response. Clin Infect Dis 56: 100-105, 2013.","DOI":"10.1093\/cid\/cis859"},{"key":"35","unstructured":"35. Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 1: 196-206, 2016."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/4\/60_5432-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T04:42:30Z","timestamp":1613796150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/4\/60_5432-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5432-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]}}}